Study of ARQ-234 for healthy adults and those with atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new medication called ARQ-234 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study looks at how the body handles single and multiple doses, and if it can help treat eczema.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You are generally healthy with no major medical conditions.
- If you have eczema, it must be moderate-to-severe and last at least 6 months.
- You must weigh between 50 and 100 kg (110 to 220 lbs) for most parts, up to 125 kg (275 lbs) for certain groups.
- You must agree to use birth control if needed, and not be pregnant or breastfeeding.
- You have no history of serious infections, allergies, or recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.
This study tests a new medication called PRA-216 for atopic dermatitis (a skin condition also known as eczema). It aims to see how safe and effective it is for people who haven't had success with topical treatments.
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
This trial tests an oral medication (capsule) for moderate to severe atopic dermatitis (eczema) that has not responded well to other treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
Hear when a new Eczema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.